Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis

2.1 Avacopan (Tavneos, CSL Vifor), 'in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)'.

2.2 The dosage schedule is available in the summary of product characteristics for avacopan.

2.3 Avacopan costs £5,547.95 per pack of 180x10 mg capsules (company submission). The company has a commercial arrangement. This makes avacopan available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.